Early Nuplazid sales boost Acadia shares

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $3.85 (17%) to $26.84 after it reported 3Q16 earnings that included stronger than expected early sales data for Nuplazid pimavanserin. Acadia launched the drug in late May, about a month after its U.S. approval to treat hallucinations and delusions associated with Parkinson's disease psychosis (see BioCentury Extra, April 29)...